This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy?

Stanley Druckenmiller's Duquesne family office has maintained Natera as its largest holding for 8 consecutive quarters. The medical diagnostics company uses liquid biopsy technology for cancer detection and other applications, showing strong growth with 57% year-over-year increase in oncology tests and 38% revenue growth. Despite persistent losses, the company has strong cash reserves and is projected to approach profitability by 2027. However, the stock has surged 87% in the past year with a lofty price-to-sales ratio of 17.

09/14/2026, 9:30 AM • The Motley Fool

State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for Investors

XLV and IXJ are two healthcare ETFs with different approaches: XLV focuses on 60 U.S. S&P 500 healthcare stocks with a low 0.08% expense ratio and stronger recent returns, while IXJ offers broader global diversification with 110 holdings across multiple countries but charges a higher 0.38% expense ratio. The choice depends on whether investors prioritize cost efficiency and domestic concentration or international diversification.

09/13/2026, 5:24 PM • The Motley Fool

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.

09/10/2026, 4:08 PM • The Motley Fool

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.

09/08/2026, 2:30 PM • The Motley Fool

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Novo Nordisk's stock has declined 66% from its 2024 high and now trades at attractive valuations compared to historical averages. While the company lost its GLP-1 weight-loss drug market lead to Eli Lilly, it is attempting a comeback through a new GLP-1 pill and a volume-driven pricing strategy. Despite significant uncertainty around its competitive position and business transition, the stock's low valuation and 3.7% dividend yield may appeal to value and dividend investors.

09/08/2026, 12:15 PM • The Motley Fool

Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics

Cloverleaf Bio, a Yale spinout RNA therapeutics company, closed a $33 million oversubscribed seed round led by 4BIO Capital with strategic participation from AbbVie Ventures, Eli Lilly, and Boehringer Ingelheim Venture Fund. The funding will advance the company's engineered tRNA platform for cancer treatment, with lead programs targeting hepatocellular carcinoma and colorectal cancer. Preclinical data shows the platform demonstrates superior potency and selectivity for cancer cells over healthy tissue.

09/08/2026, 7:00 AM • GlobeNewswire

Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - SNS Insider

The radioligand therapy market is projected to grow at an 18.2% CAGR through 2035, driven by increased prostate cancer and neuroendocrine tumor cases, FDA approvals for PSMA-targeted therapies like Pluvicto, and expanded isotope production capacity. North America dominates with 80.5% market share, while Asia-Pacific is the fastest-growing region at 21.5% CAGR.

09/07/2026, 8:30 PM • GlobeNewswire

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

Eli Lilly's GLP-1 weight-loss drugs (Mounjaro, Zepbound) currently drive nearly two-thirds of revenue, but face competition and patent expiration risks. The company is strategically acquiring smaller biotech firms across autoimmune, mental health, sleep disorders, and infectious disease spaces to diversify its pipeline and prepare for when GLP-1 drugs are no longer its primary revenue driver.

09/07/2026, 5:15 PM • The Motley Fool

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

09/07/2026, 6:52 AM • GlobeNewswire

Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - SNS Insider

The global atopic dermatitis drugs market is projected to grow from USD 15.92 billion in 2025 to USD 33.42 billion by 2035, driven by increased adoption of biologic therapies, JAK inhibitors, and novel treatments. North America leads with 36% market share, while Asia-Pacific shows the fastest growth. Biologics dominate with 42% market share, though high costs and JAK inhibitor safety warnings present challenges.

09/04/2026, 8:30 PM • GlobeNewswire

2 Stocks Down 8% or More That Are Screaming Buys Right Now

The article highlights two beaten-down stocks as potential buying opportunities: Intuitive Surgical, down 34% year-to-date, is positioned to benefit from its da Vinci 5 surgical system's advanced features and expanding market; Novo Nordisk, down 8% this year, has promising GLP-1 pipeline candidates like amycretin and UBT251 that could help it regain market share in the weight-loss drug sector.

09/04/2026, 10:30 AM • The Motley Fool

Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress

Nxera Pharma announced it will receive an $8.6 million milestone payment from Centessa Pharmaceuticals (a subsidiary of Eli Lilly) following late-stage development progress on selective orexin receptor 2 (OX2R) agonist candidates. The payment will be recognized as revenue in Q3 2026. Nxera retains rights to future development, commercialization milestones, and royalties from the OX2R agonist programs.

09/03/2026, 2:34 AM • GlobeNewswire

2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now

Bristol Myers Squibb and Pfizer are recommended as undervalued pharmaceutical stocks offering above-average dividend yields. BMY offers a safer 3.76% yield with a sustainable 45% FCF payout ratio and growing oncology portfolio, while PFE provides a higher 6.04% yield but with a riskier 89% payout ratio. Both trade at steep discounts to peers despite facing patent expiration challenges.

09/02/2026, 12:30 PM • The Motley Fool

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ

Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.

09/02/2026, 12:12 PM • The Motley Fool

Vanguard Health Care ETF vs Simplify Health Care ETF

Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 1.5% dividend yield, while Simplify Health Care ETF (PINK) provides active management with higher 1-year returns (32.4% vs 29.3%) but charges 0.51% in fees. The author recommends Simplify despite Vanguard's better year-to-date performance, citing Simplify's superior longer-term returns and its pro bono model donating profits to breast cancer research.

09/01/2026, 3:12 PM • The Motley Fool